Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $181
Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ: RVMD ) with a Outperform and raises the price target from $165 to $181.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.